Literature DB >> 29928314

Anticoagulant Therapy for Acute Coronary Syndromes.

Eunice Nc Onwordi1, Amr Gamal2, Azfar Zaman2.   

Abstract

Anticoagulation in conjunction with antiplatelet therapy is central to the management of acute coronary syndromes (ACS). When used effectively it is associated with a reduction in recurrent ischaemic events including myocardial infarction and stent thrombosis as well as a reduction in death. Effective ischaemic risk reduction whilst balancing bleeding risk remains a clinical challenge. This article reviews the current available evidence for anticoagulation in ACS and recommendations from the European Society of Cardiology.

Entities:  

Keywords:  Acute coronary syndrome; anticoagulation; bivalirudin; bleeding; fondaparinux; heparin; thrombogenesis

Year:  2018        PMID： 29928314      PMCID： PMC5980649          DOI： 10.15420/icr.2017:26:1

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN： 1756-1485


  65 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 2.  Intrinsic pathway of coagulation and arterial thrombosis.

Authors:  David Gailani; Thomas Renné
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

3.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

4.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

5.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

6.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

7.  Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Authors:  P Théroux; D Waters; S Qiu; J McCans; P de Guise; M Juneau
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

8.  Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; William E Brady; Harvey D White; Keith A A Fox; Joanne Palmisano; Karen E Ramsey; David W Bilheimer; Eldrin F Lewis; M Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  Eur Heart J       Date:  2004-10       Impact factor: 29.983

9.  Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.

Authors:  Gregg W Stone; James H Ware; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; E Magnus Ohman; Harvey D White; Frederick Feit; Antonio Colombo; Brent T McLaurin; David A Cox; Steven V Manoukian; Martin Fahy; Tim C Clayton; Roxana Mehran; Stuart J Pocock
Journal:  JAMA       Date:  2007-12-05       Impact factor: 56.272

Review 10.  Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.

Authors:  Johanne Silvain; Farzin Beygui; Olivier Barthélémy; Charles Pollack; Marc Cohen; Uwe Zeymer; Kurt Huber; Patrick Goldstein; Guillaume Cayla; Jean-Philippe Collet; Eric Vicaut; Gilles Montalescot
Journal:  BMJ       Date:  2012-02-03
View more
  4 in total

1.  Association of Prolonged Emergency Department Length of Stay with Adverse Events in Patients with Non-ST-Elevation Acute Coronary Syndrome.

Authors:  Thanya Limapichat; Sakarin Kaewyingyong
Journal:  Open Access Emerg Med       Date:  2022-03-10

Review 2.  Fondaparinux: A cornerstone drug in acute coronary syndromes.

Authors:  Mohammed Yunus Khan; Chandrashekhar K Ponde; Viveka Kumar; Kumar Gaurav
Journal:  World J Cardiol       Date:  2022-01-26

3.  Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.

Authors:  Mohammadreza Amirsadri; Valiollah Hajhashemi; Amir Shahriar Asemi
Journal:  J Res Pharm Pract       Date:  2021-08-03

4.  Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.

Authors:  Jamshed Dalal; J C Mohan; Sunil Sathe; A Sreenivas Kumar; Jagdish Hiremath; Mohammed Yunus Khan; Kumar Gaurav; Amey Mane; Sucheta Pandit; Bhavesh Meel; Anand Subramaniyan
Journal:  Cardiol Ther       Date:  2022-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.